Dan’s practice focuses on Hatch-Waxman ANDA litigation, chemicals litigation, and contested proceedings before the United States Patent and Trademark Office with an emphasis on the pharmaceutical and chemical arts. Dan has counseled clients on a wide range of pharmaceuticals in a variety of formulations for use in the treatment of breast and prostate cancers, renal disease, hypertension, arrhythmias, diabetes, epilepsy, hormonal disorders, leukemia, osteoporosis, Alzheimer’s, and multiple sclerosis.
Prior to law school, Dan worked as a medicinal chemist for Agouron Pharmaceuticals before receiving his Master’s Degree from the University of Pittsburgh for his synthetic studies on the viridin family of kinase inhibitors.
Dan has spent his entire career in private practice at Fitzpatrick.
Dan helped secure a complete victory in Hatch-Waxman litigation for clients Bone Care Int. and Genzyme against several generic drug manufacturers, including Pentech/Cobrek, Roxane, Sandoz, and Anchen. In district court cases in Illinois and Delaware, he helped win a ruling that each generic drug manufacturer’s vitamin D analog drugs infringed a patent held by his clients, and that those patents were not invalid for obviousness, lack of written description/enablement, and inoperability.